Overview

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Status:
Completed
Trial end date:
2016-05-19
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
Details
Lead Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept